STRATIFYING CANCER PATIENTS HARBOURING ONCOGENIC MUTATIONS IN THE E3 UBIQUITIN LIGASE RNF43

摘要

The present invention relates to stratifying cancer patients harbouring oncogenic mutations in the E3 ubiquitin ligase RNF43. More particularly, the invention relates to stratifying patients based on whether they have a loss of function mutation, a dominant negative mutation or a silent mutation in RNF43, thereby identifying which patients will be likely to respond to Wnt-pathway inhibitors and those that won't respond and can avoid incorrect treatment and possible side effects of Wnt-pathway inhibitor treatment.